



SUVEN Life Sciences

Communication to investors **Dec 2013**

4-Feb-14

2013-14 Q3 results



Risk statement

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause these statements to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.



FINANCIAL QUICK VIEW

		Q3 Dec 13	PE Dec 13
Growth in revenue		92%	109%
Growth in PAT		370%	403%
Growth in EBIDTA		266%	333%
Growth in Pre-R&D EBIDTA		167%	222%
Increase in R&D Costs		5%	43%
R&D to sales		8%	9%




MAJOR PROFITABILITY RATIOS

	Q3 Dec 13	PE Dec 13
PAT to Income	30%	29%
EBIDTA to Income	46%	45%
Cash Flow to Income	32%	31%
Pre-R&D EBITDA to Income	54%	54%




INCOME COMPARISON






PROFIT COMPARISON






EBIDTA COMPARISON






R & D – EXPENDITURE






PRE-R&D EBIDTA





PRE-R&D CASHFLOW





Status for the period ended Dec 2013

- Suven has **614** product patents for **18** inventions and **35** process patents
- Number of active CRAMS projects during period - **98**
- SUVN 502 undergoing Phase **1b** clinical trial in USA